| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Kettering-Meyer Laboratory, Southern Research Institute,2 Birmingham, Alabama
We have shown that the in vivo treatment of Fortner plasmacytomas with cyclophosphamide can lead to strong inhibitions of both deoxyribonucleic acid nucleotidyl transferase and thymidylate kinase activities in the soluble cell fractions. However, in allowing only 2 hr for the inhibitor to act, the effect observed on the transferase was an unexplained stimulation rather than an inhibition.
We have also provided some evidence that the inhibition of growth precedes the inhibition of deoxyribonucleic acid nucleotidyl transferase activity.
1 This investigation was supported by grants from the Alfred P. Sloan Foundation, the Charles F. Kettering Foundation, The John A. Hartford Foundation, Inc., and by the Cancer Chemotherapy National Service Center, National Cancer Institute, under the National Institutes of Health Contract No. SA-43-ph-2433. A preliminary report was presented before the American Association for Cancer Research, Chicago, Illinois, April 1964.
2 Affiliated with the Sloan-Kettering Institute, New York, New York.
Received 6/21/65.
Revised 1/10/66.
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |